{{Rsnum
|rsid=4142237
|Gene=HPCAL1
|Chromosome=2
|position=10390424
|Orientation=plus
|GMAF=0.3714
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=HPCAL1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 65.5 | 29.2 | 5.3
| HCB | 14.0 | 50.7 | 35.3
| JPT | 11.5 | 41.6 | 46.9
| YRI | 39.0 | 44.5 | 16.4
| ASW | 36.8 | 47.4 | 15.8
| CHB | 14.0 | 50.7 | 35.3
| CHD | 18.3 | 45.0 | 36.7
| GIH | 66.3 | 30.7 | 3.0
| LWK | 34.9 | 48.6 | 16.5
| MEX | 37.9 | 46.6 | 15.5
| MKK | 55.1 | 39.1 | 5.8
| TSI | 70.6 | 28.4 | 1.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs4142237
|Name_s=
|Gene_s=HPCAL1
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.000001. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109416
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4142237
|overall_frequency_n=38
|overall_frequency_d=128
|overall_frequency=0.296875
|n_genomes=28
|n_genomes_annotated=0
|n_haplomes=35
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}